Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6462]

FDA approves axicabtagene ciloleucel CAR T cell therapy for relapsed B cell lymphoma

FDA approves axicabtagene ciloleucel CAR T cell therapy for relapsed B cell lymphoma

Polygenic risk scores can refine breast cancer risk assessment for BRCA negative high-risk women

Polygenic risk scores can refine breast cancer risk assessment for BRCA negative high-risk women

Understanding how inflammatory cells impair promising tumour treatments

Understanding how inflammatory cells impair promising tumour treatments

Microbiome disruptions found in breast cancer tissues

Microbiome disruptions found in breast cancer tissues

Pembrolizumab more than doubled median overall survival compared to chemotherapy in PD-L1 high mNSCLC

Pembrolizumab more than doubled median overall survival compared to chemotherapy in PD-L1 high mNSCLC

'Undruggable' cancer protein successfully targeted with new drug combination

'Undruggable' cancer protein successfully targeted with new drug combination

EMA issues PRIME designation for entrectinib in NTRK fusion solid tumours

EMA issues PRIME designation for entrectinib in NTRK fusion solid tumours

Battling flames increases firefighters' exposure to carcinogens

Battling flames increases firefighters' exposure to carcinogens

Drug yields high response rates for lung cancer patients with harsh mutation

Drug yields high response rates for lung cancer patients with harsh mutation

New bowel cancer drug target discovered

New bowel cancer drug target discovered

More from ecancer